Ceftriaxone
- Generic Name
- Ceftriaxone
- Brand Names
- Rocephin
- Drug Type
- Small Molecule
- Chemical Formula
- C18H18N8O7S3
- CAS Number
- 73384-59-5
- Unique Ingredient Identifier
- 75J73V1629
- Background
Ceftriaxone is a broad-spectrum third-generation cephalosporin antibiotic. It has a very long half-life compared to other cephalosporins and is high penetrable into the meninges, eyes, and inner ear. Ceftriaxone has broader and stronger gram-negative coverage then first or second-generation cephalosporins, but worse activity against methicillin-susceptible S...
- Indication
Ceftriaxone is used for the treatment of the infections (respiratory, skin, soft tissue, UTI, ENT) caused by susceptible organisms. Organisms that are generally susceptible to ceftriaxone include S. pneumoniae, S. pyogenes (group A beta-hemolytic streptococci), coagulase-negative staphylococci, Some Enterobacter spp, H. influenzae, N. gonorrhoeae, P. mirabil...
- Associated Conditions
- Abscess Brain, Bacterial Endocarditis, Bacterial Infections, Bacterial Sinusitis, Bone and Joint Infections, Chancroid, Community Acquired Pneumonia (CAP), Conjunctivitis gonococcal neonatal, Epididymitis, Epiglottitis, Gonococcal arthritis, Gonococcal infection of pharynx, Gonococcal pelvic inflammatory disease, Intraabdominal Infections, Lower respiratory tract infection bacterial, Lyme Neuroborreliosis, Meningitis, Bacterial, Ophthalmia neonatorum due to gonococcus, Postoperative Infections, Prosthetic Joint Infections, Sepsis Bacterial, Septic Arthritis, Shigellosis, Skin and Subcutaneous Tissue Bacterial Infections, Syphilis, Vulvovaginitis gonococcal, Whipple Disease, Bacterial otitis media, Complicated Urinary Tract Infection caused by susceptible bacteria, Disease caused by Salmonella typhi, Susceptible Bacterial Infections, Uncomplicated Gonorrhea, Uncomplicated Urinary tract infection bacterial
- Associated Therapies
- -
Intravenous Azithromycin Plus Intravenous Ceftriaxone Followed by Oral Azithromycin With Intravenous Levofloxacin Followed by Oral Levofloxacin for the Treatment of Moderate to Severely Ill Hospitalized Patients With Community Acquired Pneumonia
- Conditions
- Interventions
- First Posted Date
- 2002-05-06
- Last Posted Date
- 2017-03-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 219
- Registration Number
- NCT00035347
- Locations
- 🇪🇸
Pfizer Investigational Site, Tarrasa, Cataluna, Spain
Prospective Comparison of Ampicillin / Amoxicillin Versus Ceftriaxone for the Treatment of Salmonella Infections in AIDS Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- University of Southern California
- Registration Number
- NCT00002052
- Locations
- 🇺🇸
Los Angeles County - USC Med Ctr, Los Angeles, California, United States
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of the Safety and Efficacy of Ceftriaxone and Doxycycline in the Treatment of Patients With Seronegative Chronic Lyme Disease
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2010-08-27
- Target Recruit Count
- 66
- Registration Number
- NCT00000938
- Locations
- 🇺🇸
Mark Klempner, Boston, Massachusetts, United States
A Pilot Study Evaluating Penicillin G and Ceftriaxone as Therapies for Presumed Neurosyphilis in HIV Seropositive Individuals
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-10-27
- Target Recruit Count
- 100
- Registration Number
- NCT00000648
- Locations
- 🇺🇸
Northwestern Univ Med School, Chicago, Illinois, United States
🇺🇸Rush Presbyterian - Saint Luke's Med Ctr, Chicago, Illinois, United States
🇺🇸Beth Israel Deaconess Med Ctr, Boston, Massachusetts, United States
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial of the Safety and Efficacy of Ceftriaxone and Doxycycline in the Treatment of Patients With Seropositive Chronic Lyme Disease
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2010-08-27
- Target Recruit Count
- 194
- Registration Number
- NCT00001101
- Locations
- 🇺🇸
Mark Klempner, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.